Malcolm J. Moore

Malcolm J. Moore

Auto-generated profile, based on publicly available information

Malcolm J. Moore

Princess Margaret Hospital, Toronto, Canada

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
David Benjamin ShultzDavid Benjamin Shultz
David Benjamin Shultz
JPJonathan Pai
Jonathan Pai
WCWayland Chiu
Wayland Chiu
KNKendall Ng
Kendall Ng
MHMadeline G Hellendag
Madeline G Hellendag
AKAlbert C Koong
Albert C Koong
NCIC Clinical Trials Group PA.3 was a randomized control trial that demonstrated improved overall survival (OS) in patients receiving erlotinib in addition to gemcitabine for locally advanced or metastatic pancreatic cancer. Prior to therapy, patients had plasma samples drawn for future study. We sought to identify biomarkers within these samples. Using the proximity ligation assay (PLA), a probe panel was built from commercially available antibodies for 35 key proteins selected from a global genetic analysis of pancreatic cancers, and used to quantify protein levels in 20 uL of patient plasma. To determine if any of these proteins levels independently associated with OS, univariate and mulitbaraible Cox models were used. In addition, we examined the associations between biomarker expression and disease stage at diagnosis using Fisher's exact test. The correlation between Erlotinib sensitivity and each biomarkers was assessed using a test of interaction between treatment and biomarker. Of the 569 eligible patients, 480 had samples available for study. Samples were randomly allocated into training (251) and validation sets (229). Among all patients, elevated levels of interleukin-8 (IL-8), carcinoembryonic antigen (CEA), hypoxia-inducible factor 1-alpha (HIF-1 alpha), and interleukin-6 were independently associated with lower OS, while IL-8, CEA, platelet-derived growth factor receptor alpha and mucin-1 were associated with metastatic disease. Patients with elevated levels of receptor tyrosine-protein kinase erbB-2 (HER2) expression had improved OS when treated with erlotinib compared to placebo. In conclusion, PLA is a powerful tool for identifying biomarkers from archived, small volume serum samples. These data may be useful to stratify patient outcomes regardless of therapeutic intervention. ClinicalTrials.gov NCT00040183

1 August 2002 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
MMM. Michael
M. Michael
DHDavid Hedley
David Hedley
AOAmit Oza
Amit Oza
RFR. Feld
R. Feld
MPMelania Pintilie
Melania Pintilie
MMM.J. Moore
M.J. Moore

3 January 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JVJoao Paulo Solar Vasconcelos
Joao Paulo Solar Vasconcelos
NCNan Chen
Nan Chen
ETEmma Titmuss
Emma Titmuss
DTDongsheng Tu
Dongsheng Tu
SBStephanie Y. Brule
Stephanie Y. Brule
JLJonathan M Loree
Jonathan M Loree
Purpose: Sidedness is prognostic and predictive of anti-EGFR efficacy in metastatic colorectal cancer (mCRC). Transverse colon has been historically excluded from several analyses of sidedness and the optimal division between left- and right-sided colorectal cancer is unclear. We investigated transverse colon primary tumor location as a biomarker in mCRC. Experimental Design: Pooled analysis of CCTG/AGITG CO.17 and CO.20 trials of cetuximab in chemotherapy-refractory mCRC. Outcomes of patients with RAS/BRAF wild-type (WT) mCRC from CO.17 and KRAS WT mCRC from CO.20 were analyzed according to location. Results: A total of 553 patients were analyzed, 32 (5.8%) with cancers from the transverse, 101 (18.3%) from right, and 420 from (75.9%) left colon. Transverse mCRC failed to reach significant benefit from cetuximab versus best supportive care (BSC) for overall survival [OS; median, 5.9 vs. 2.1 months; HR, 0.63; 95% confidence interval (CI), 0.28–1.42; P=0.26] and progression-free survival (PFS; median, 1.8 vs. 1.3 months; HR, 0.57; 95% CI, 0.26–1.28; P=0.16). Analyzing exclusively patients randomized to cetuximab, right-sided and transverse had comparable outcomes for OS (median, 5.6 vs. 5.9 months; HR, 0.82; 95% CI, 0.50–1.34; P=0.43) and PFS (median, 1.9 vs. 1.8 months; HR, 0.78; 95% CI, 0.49–1.26; P=0.31). Patients with left-sided mCRC had superior outcomes with cetuximab compared with transverse for OS (median, 9.7 vs. 5.9 months; HR, 0.42; 95% CI, 0.27–0.67; P=0.0002) and PFS (median, 3.8 vs. 1.8 months; HR, 0,49; 95% CI, 0.31–0.76; P=0.001). Location was not prognostic in patients treated with BSC alone. Conclusions: Transverse mCRC has comparable prognostic and predictive features with right-sided mCRC.

1 January 2009 in Acta Oncologica
Verified
Journal Article
Open access
ECElaine Cheng
Elaine Cheng
RBRudolph Dominik Berthold
Rudolph Dominik Berthold
MMMalcolm J. Moore
Malcolm J. Moore
IDIgnacio Duran
Ignacio Duran
(2009). Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors. Acta Oncologica: Vol. 48, No. 3, pp. 475-476.

1 October 1993 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
MMM J Moore
M J Moore
CEC Erlichman
C Erlichman
LGLaura Grau
Laura Grau
SFS Fine
S Fine
Increased activity against colorectal cancer by 5-fluorouracil (5-Fu) modulation with leucovorin (LV) and/or interferon (IFN) has been reported. In this study 22 patients with measurable advanced pancreatic cancer received 5-Fu 375 mg/m2 and LV 20 mg/m2 by i.v. bolus daily x 5 every 28 days plus IFN-alpha 3 million units/m2 s.c. There were three out of 21 (14%) responses lasting from 4 to 8 months. Sixteen patients (73%) had one or more episodes of grade 3 or greater toxicity (stomatitis, diarrhea or fatigue). While this combination has some activity against pancreatic cancer, its toxicity limits its potential as a palliative treatment.